Approval in a strategic healthcare hub strengthens regional growth strategy and supports clinical adoption of fluorescence-guided surgery  

UltraGreen.ai, a global leader in fluorescence-guided surgery and digital health solutions, announced regulatory approval for Verdye (indocyanine green for injection) in Singapore.  

This approval represents a strategic step in the Company’s Southeast Asia growth strategy,  expanding its addressable market and strengthening its presence in a key regional healthcare  hub. 

Singapore plays a critical role as a centre for clinical excellence and regional influence,  supporting broader adoption of advanced surgical technologies across Southeast Asia.  

This approval enables UltraGreen.ai to advance commercialisation efforts, deepen  partnerships with leading healthcare institutions, and support clinical adoption of  fluorescence-guided surgery. 

Fluorescence-guided surgery using ICG is now widely adopted across multiple surgical  specialties, including oncology, colorectal, reconstructive, and vascular procedures. Verdye’s  entry into Singapore enhances access to a globally established product with a strong track  record across international markets. 

Scaling an Integrated Fluorescence-Guided Surgery Platform 

UltraGreen.ai’s approach extends beyond individual product approvals. The Company  continues to build a comprehensive fluorescence-guided surgery ecosystem, combining  pharmaceutical products, compatible imaging hardware, and AI-powered data platforms  designed to support surgical decision-making, standardisation and improved patient  outcomes. 

It further strengthens the Company’s ability to scale this platform regionally, supporting long term growth through increased procedural adoption and recurring product utilisation.  

Commenting on the approval, Ravi Sajwan, Chief Executive Officer of UltraGreen.ai, said:

“Singapore is a strategically important market for UltraGreen.ai — not only for its world-class  healthcare system, but also for its role as a regional reference point for clinical adoption across  Southeast Asia. This approval reinforces our strong regulatory execution and clear momentum  in our regional strategy. We are well positioned to support surgeons with proven fluorescence 

guided solutions while laying the groundwork for continued growth and innovation across  Southeast Asia.” 

This latest milestone builds on UltraGreen.ai’s recent IPO and regulatory approval of Verdye  in the Philippines, underscoring strong execution and the Company’s long-term commitment  to advancing precision surgery through high-quality pharmaceutical, imaging, and data-driven  solutions. Verdye is now approved in 41 countries globally, with the IC-Flow™ imaging system  cleared in 45 markets, reflecting the Company’s expanding international footprint and ability  to scale its integrated fluorescence-guided surgery platform.